Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.47 |
| ▸ | USP2 | O75604 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.47 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968241 | 0.82 | LDHA (0.44) | CYP1A2CYP3A4USP2CYP2C19CYP2C9 | |
| SCHEMBL1970118 | 0.82 | KMO (0.50) | KMOCYP1A2CYP3A4USP2CYP2C19 | |
| SCHEMBL1970072 | 0.82 | KMO (0.50) | KMOCYP1A2CYP3A4CYP2C19CSNK1D | |
| SCHEMBL1968017 | 0.81 | KDM4E (0.44) | CYP1A2CYP3A4USP2CYP2C19CYP2C9 | |
| SCHEMBL1970226 | 0.79 | LMNA (0.54) | CYP1A2CYP3A4CYP2C19CYP2C9HSD17B10 | |
| SCHEMBL30189226 | 0.78 | DHODH (0.50) | KMOTSHRALDH1A1DCLRE1BCSNK2A2 | |
| SCHEMBL10358320 | 0.78 | TDP1 (0.57) | CYP1A2ALDH1A1MAPK1CSNK2A1LMNA | |
| SCHEMBL1971235 | 0.77 | KMO (0.47) | KMODCLRE1BCSNK2A2CSNK2BCSNK1D | |
| SCHEMBL8073486 | 0.76 | HCRTR2 (0.46) | KMODCLRE1BCSNK2A2CSNK2BPLK4 | |
| SCHEMBL4422802 | 0.75 | KMO (0.46) | KMOALDH1A1DCLRE1BCSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174634-A1 | Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-30 | — | — | US | disclosed |
| EP-4259620-A1 | ALDEHYDE DEHYDROGENASE INHIBITORS AND THEIR THERAPEUTIC USE | Cancer Research Technology Limited (GB) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022123039-A1 | ALDEHYDE DEHYDROGENASE INHIBITORS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022123039-A1 | ALDEHYDE DEHYDROGENASE INHIBITORS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-06-16 | — | — | WO | disclosed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| CN-102164896-A | Phenethylamide derivatives and their heterocyclic analogues | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | KMO 1349/4885CYP1A2 1070/4885CYP3A4 1054/4885 |
| US-20240174634-A1 | Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use | ALDH2, ALDH1A1, ALDH3A1 | KMO 1358/4885CYP1A2 450/4885CYP3A4 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.